首页|达格列净与利格列汀在胰岛素控制不佳的肥胖型T2DM患者中的降糖效果比较

达格列净与利格列汀在胰岛素控制不佳的肥胖型T2DM患者中的降糖效果比较

扫码查看
目的 比较达格列净与利格列汀在胰岛素控制不佳的肥胖型T2DM患者中的降糖效果.方法 选取肥胖型T2DM患者 74 例为研究对象,随机分为达格列净组与利格列汀组,每组 37 例,分别予以达格列净、利格列汀药物进行治疗,两组均干预30d.对比两组空腹血糖(FBG)、餐后2h血糖(2h PBG)、糖化血红蛋白(HbA1c);对两组身体质量指数(BMI)、腰围(WC)及体脂肪率(FAT)进行比较.结果 经干预后,两组患者脂代谢水平较干预前有所下降,但利格列汀组的FBG(8.31±0.71)、2h PBG(9.13±1.63)和HbA1c(8.86±0.82)明显要优于达格列净组(9.78±0.91)、(10.37±1.94)和(8.11±0.45);两组肥胖指标均有所改善,但利格列汀组的下降趋势要优于达格列净组,差异有统计学意义(P<0.05).结论 达格列净与利格列汀在胰岛素控制不佳的肥胖型T2DM患者干预中,能有效控制血糖和降低患者体重,值得临床应用.
T2DM Comparison of the Hypoglycemic Effect of Daggliptin and Liggliptin in Obese T2DM Patients with Poor Insulin Control
Objective To compare the hypoglycemic effect of daggliptin and liggliptin in obese T2DM patients with poor insulin control.Methods A total of 74 patients diagnosed with obese T2DM were selected as the study subjects.They were randomly divided into dagliazine group and lipliptin group,with 37 cases in each group.Both groups were treated with dagli-azine or lipliptin,respectively.Fasting blood glucose(FBG),postprandial 2h blood glucose(2h PBG)and glycosylated hemoglobin(HbA1c)were compared between the two groups.Body mass index(BMI),waist circumference(WC)and body FAT percentage(FAT)were compared between the two groups.Results After intervention,the level of lipid metabolism in both groups de-creased compared with that before intervention.However,the FBG(8.31±0.71),2h PBG(9.13±1.63)and HbA1c(8.86±0.82)in Ligliptin group were significantly better than those in Dagliegine group(9.78±0.91),(10.37±1.94)and(8.11±0.45).Obesity in-dexes in both groups were improved,but the decreasing trend in the lipliptin group was better than that in the dagliegine group,with statistical significance(P<0.05).Conclusion Daggliptin and liggliptin can effectively control blood sugar and re-duce the weight of obese T2DM patients with poor insulin control,which is worthy of clinical application.

DaglijingLinagliptininsulinObese T2DM

刘晓燕、刘芳、徐凤梅

展开 >

鹤壁煤业(集团)有限责任公司总医院内分泌科,河南 鹤壁 458000

达格列净 利格列汀 胰岛素 肥胖型

2024

哈尔滨医药
哈尔滨市医学会

哈尔滨医药

影响因子:0.697
ISSN:1001-8131
年,卷(期):2024.44(3)